Skip to Content

Marcella (Marcy) Johnson, M.S.

Director, Quantitative Research

Degree

  • M.S. in Statistics, Texas A & M University, College Station, TX

Areas of Interest

  • Clinical trial design
  • Survival analysis

Peer-reviewed Publications

Berry DA,Ueno NT, Johnson MM, Lei X,Caputo J, Smith DA,Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011: 29(24):3224-3231.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni A, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29(24):3214-3223.

Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29(16):2199-2205.

Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011; 96(3):717-725.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17(2):229-35.

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res 2010 Nov 22. [Epub ahead of print]

Jonasch E, Corn P, Pagliaro L, Warneke CL,  Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe R,  Wright JJ,  Tannir N. Upfront Randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116(1):57-65.

Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P; AJCC Melanoma Task Force (including Johnson MM). Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 2010; 17(8):2006-2014.

Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O’Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis in cancer patients during multi-cycle chemotherapy: a double-blind, randomized trial. Ann Int Med 2010; 153(6):358-367.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Roe AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield, PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009; 19(1):42-49.

Tu SM, Jones D, Mathew P, Johnson MM, Wong FC, Logothetis C. Phase I study of concurrent weekly docetaxel and repeated 153sm-lexidronam in patients with androgen-independent prostate cancer. J Clin Oncol 2009; 27(20):3319-3324.

Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, General RD, Aparicio A, Pagliaro LC, Guo CC, Kuban DA, Johnson MM, Logothetis CJ, Lin SH, PistersLL. Ductal adenocarcinoma of the prostate – clinical features and implications after local therapy. Cancer 2009; 115(13):2872-2880.

Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 2009; 36:1157–1163.

Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA. Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol 2009; 181(3):1028-1034.

Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 2009; 129(6):1483-1488.

Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva LdeP, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008; 14(19):6296-6301.

Kim KB, Eton O, Davis D, Frazier M, McConkey D, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of matinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99(5):734-740.

Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26(26):4296-4303.

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26(6):624-633.

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6):826-836.

Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res 2008; 10(3):R44.

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos N, Hwu WJ, Kim K, Hwu P. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 2008; 5(2):201-207.

Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S,  Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007; 13(19):5816-5824.

Chakravarti N, Lotan R, Diwan AH, Warneke CL, Johnson MM, Prieto VG. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res 2007; 13(16):4817-4824.

Burjonroppa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW, Lenihan DJ. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 2007; 30(3):287-293.

Tellez CS, Davis DW, PrietoVG, Gershenwald JE, Johnson MM, McCarty M, Bar-Eli M. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 2007; 127(2):387-393.

Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res 2007; 31(2):139-145.

Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJF, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M. Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. Clin Cancer Res 2006; 12(22):6709-6715.

Gannon CJ, Rousseau DL, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 2006; 107(11):2647-2652.

Westney OL, Scott S, Wood C, Eddings T, Johnson MM, Taylor JM, McGuire E, Pisters LL. Suburethral sling at the time of radical prostectomy in patients at high risk for postoperative incontinence. BJU Int 2006; 98(2):308-313.

Aloia T, Gershenwald JE, Ross MI, Lee JE, Johnson MM, Cormier JN, Ng C, Mansfield PF. Utility of computed tomography and magnetic resonance staging prior to completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24(18):2858-2865.

Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006; 119(4):861-866.

Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 2006; 25(28):3956-3962.

Simeone A, Colella S, Krahe R, Johnson MM, Mora E, Tari AM. N-(4-Hydroxyphenyl) retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis 2006; 27(3):568-577.

Ludwick JJ, Rossmann SN, Johnson MM, Edmonds JL. The bacteriostatic properties of ear tubes made of absorbable polylactic acid. Int J Pediatr Otorhinolaryngol 2006; 70(3):407-410.

Feng J, Lenihan DJ, Johnson MM, Karri V, Reddy CVR. Cardiac sequelae in Brooklyn after the September 11 terrorist attacks. Clin Cardiol 2006; 29(1):13-17.

Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006; 106(4):900-906.

Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2 alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005; 65(23):11185-11192.

Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult aute lymphoblastic leukemia. Blood 2005; 106(13):4303-4307.

Choi H, Johnson MM. Reply. Am J Roentgenol 2005; 185(5):1366-1367.

Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104(8):1590-1602.

Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12(8):587-596.

Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM. N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005; 26(5):1000-1007.

Choi H, Charnsangavej C, Faria Sde C, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004; 183(6):1619-1628.

Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004; 101(12):2837-2842.

Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, Madoff DC, Morello FA, Murthy R, Hicks ME. Use of inferior vena caval filters and survival in patients with malignancy. Cancer 2004; 101(8):1902-1907.

Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004; 101(5):999-1008.

Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res 2004; 10(16):5531-5536.

Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Kantarjian HM, Armitage JO, Albitar M. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28(6):595-604.

Wu X, Zhao H, Do KA, Johnson MM, Dong J, Hong WK, Spitz MR. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 2004; 10(12 Pt 1):3988-3995.

Yang WT, Whitman GJ, Johnson MM, Bolanos-Clark M, Kushwaha AC, Hunt KK, Dempsey PJ. Needle localization for excisional biopsy of breast lesions: comparison of effect of use of full-field digital versus screen-film mammographic guidance on procedure time. Radiology 2004; 231(1):277-281.

Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100(7):1478-1483.

Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M, Tari AM. Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 2004; 64(4): 1224-1228.

Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45(1): 17-21.

Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004; 140(1):18-25.

Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O’Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin’s Lymphoma or Hodgkin’s disease. Br J Haematol 2003; 123(5):850-857.

Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA. High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncol Rep 2003; 10(5):1317-1320.

Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, Guitart J, Horenstein MG, Ming ME, Piepkorn MW, Rabkin MS, Reed JA, Selim MA, Trotter MJ, Johnson MM, Shea CR. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol 2003; 120(2):203-208.

Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10(5):569-574.

Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol. Cancer Causes Control 2003; 14(2):131-138.

Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukemia. Br J Haematol 2003; 120(3):452-456.

Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003; 5(1):26-31.

Abstracts

Vadhan-Raj S, Hagemeister F, Fayad L, Zhou X, O’Roark S, McLaughlin P, Rodriguez  AM, Fanale M, Pro B, Johnson MM, Bueso-Ramos C, Younes A, Kwak L, Romaguera J. Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. [Poster presented at the 52nd ASH Annual Meeting and Exposition, Orlando, Florida, December 4-7, 2010].

Long GV, Atkins MB, Warneke CL, Carlino MS, DeRose E, Johnson MM, Brown PT, Roberson F, Gardner J, Alvarado G, Lee MY, Kefford RF, Gershenwald JE. Unraveling the Prognostic Heterogeneity in Patients with Advanced Melanoma (MM) Between Australia (OZ) and the United States (US): The PHAMOUS STUDY. [Poster presented at Society for Melanoma Research, 7th International Melanoma Congress, Sydney, Australia, November 2010].

Carlino MS, Atkins MB, Warneke CL, Long GV, DeRose ER, Johnson MM, Brown PT, Lee MY, Gardner J,  Hamilton A, Alvarado G, Kefford R, Gershenwald JE. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. [Poster presented at Society for Melanoma Research, 7th International Melanoma Congress, Sydney, Australia, November 2010].

Atkins MB, Long GV, Warneke CL, Carlino MS, DeRose E, Johnson MM, Brown PT, Lee MY, Kefford RF, Gershenwald JE. Unraveling the Prognostic Heterogeneity in Patients with Advanced Melanoma Between Australia and the United States: Preliminary Report of the PHAMOUS Study. [Poster presented, American Society Clinical Oncology Annual Meeting, June 2010].

Caudle A, Ross MI, Prieto VG, Warneke CL, Lee JE, Johnson MM, Gardner, Royal, Cormier, Lucci, Gershenwald JE. Mitotic Rate Predicts Sentinel Lymph Node Involvement in Cutaneous Melanoma: Impact of the 7th Edition AJCC Melanoma Staging System. [Presented at the 2010 annual meeting of the Society of Surgical Oncology, St. Louis, Missouri, March 3-7, 2010].

Kebriaei P, Jones D, Johnson MM, Gutierrez K, Giralt S,de Lima M, Korbling M, Khouri IF, Popat U, Qazilbash MH, Alousi A, Ciurea S, Cooper L, Shpall E, Champlin R. Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. [Presented at the 2009 annual meeting of the International Umbilical Cord Blood Transplantation Symposium, Los Angeles, CA, June 5-6, 2009].

Berry DA, Ueno NT, Johnson MM, Lei X, Smith DA, Caputo J, Yancey LJ, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. [Poster presented at the 2008 meeting of the San Antonio Breast Cancer Symposium].   

Albarracin CT, Sigauke E, Whitman G, Yang WT, Resetkova E, Johnson MM, Nguyen CV, Sneige N. Atypical and Columnar Cell Lesions in Breast Needle Biopsies for Indeterminate Microcalcifications: Predictors of Higher Risk Findings Requiring Surgical Excision. [Poster presented at the 2008 San Antonio Breast Cancer Symposium]. 

Ekmekcioglu S, Johnson MM, Gershenwald JE, Prieto VG, Grimm EA. iNOS Expression in Tumor Cells and Tumor Associated Macrophages in Melanoma. [Poster presented at Chemical and Biological Aspects of Inflammation and Cancer, October 14-17, 2008].

Gershenwald JE, Morton DL, Thompson JF, Kirkwood JM, Soong S, Balch CM, Eggermont AM, Sondak VK, Johnson MM, Warneke C, Collaborators of the AJCC/UICC Melanoma Task Force. Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4895 melanoma patients. [Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, May 2008].

Wang Y, Kesmodel SB, Vo AH, Liu H, Chun YS, Gershenwald JE, Cormier JN, Ross MI, Wang DY, McClain DM, Schacherer CW, Henderson L, Liu P, Johnson MM, Berry DA, Reveille JD, Lee JE. Association of the TGF-Beta1 codon 10 T polymorphism with improved outcomes in early-stage melanoma patients. [Presented at the 2008 annual meeting of the American Association of Cancer Research, San Diego, CA, April 12-16, 2008]. 

Gershenwald J, Thompson J , Warneke C, Ross M, Johnson M, McMasters K, Delman MK, Sabel M, Noyes D, Kraybill W, Coit D, Leong S, Eggermont A. (Re)-Defining Indications For Sentinel Lymph Node Biopsy (SLNB) in Patients (Pts) With Thin Melanoma - Preliminary Results of an International Thin Melanoma Working Group. [Presented at the 2008 meeting of the International Sentinel Node Society, Sydney, Australia, February 18-20, 2008]. 

Berry DA, Ueno NT, Johnson MM, Lei X, Lopez V, Caputo J, Yancey LJ, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials. [Presented at the 2007 San Antonio Breast Cancer Symposium].   

Kim KB, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Johnson MM, Colevas DA, Prieto VG. A Randomized Phase II Study of Cilengitide (EMD 121974) in Patients with Metastatic Melanoma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings. Vol 25, No. 18S, Part I (June 20 Supplement), 2007: 8548.

Chun YS, Wang Y, Gershenwald JE, Ross MI, Johnson MM, Liu P, Schacherer CW, Reveille JD, Lee JE. HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients. Abstract ASCO No. 8503. [Presented at the 2007 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2007]. 

Lee JE, Wang Y, Vo A, Gershenwald JE, Ross MI, Johnson MM, McClain DM, Jin R. Association of HLA class II alleles with melanoma incidence. [Presented at the 14th SPORE Investigators’ Workshop, Baltimore, MD, July 2006].

Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ. Preliminary results of a randomized placebo-controlled double-b. [Presented at the 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006].

Andtbacka RH, Gershenwald JE, Prieto VG, Johnson M, Diwan H, Lee JE, Mansfield PF, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. [Presented at the 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006].

Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, Sayegh GG, Johnson MM, Gagel RF, Hortobagyi GN. Osteonecrosis of the Jaw in Patients Receiving Intravenous Bisphosphonate Therapy. [Poster presented at the 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006].

Mousallem C, Lopez A, Moore S, Gauthier AM, Johnson M, Ibrahim N. Fulvestrant (F) in metastatic breast cancer: standard dose (Std) vs loading dose (Ld). A retrospective study. [Presented at the 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006].

Sun X, Wang E, Jones DM, Shen H, Johnson MM, Issa JP, Amin H, Ginsberg CF, Kantarjian HM, Andreeff M, Kornblau SM, Glassman AB, Arlinghaus RB. SOX4 Gene Expression in Human Leukemia. [Poster presented at the American Association for Cancer Research Annual Meeting, Washington, D.C., April 1- 5, 2006].

Guray M, Sun M, Albarracin CT, Edelweiss M, Johnson MM, Esteva FJ, Yu D, Sahin AA. Significant loss of PTEN protein expression in lymph node metastases of primary breast cancer: An immunohistochemical study using tissue microarray. Laboratory Investigation. Vol 86 (Suppl 1), 2006: 29A.

Prieto VG, Diwan AH, Lazar AFJ, Johnson MM, Schacherer C, Gershenwald, JE. Histologic quantification of tumor size in sentinel lymph node metastases correlates with prognosis in patients with cutaneous malignant melanoma. Laboratory Investigation. Vol 86 (Suppl 1), 2006: 87A.

Prieto VG, Mourad-Zeidan AA, Johnson MM, Diwan AH, Lazar AJ, Shen SS, Reed JA, Bar-Eli M. Analysis of Galectin-3 Expression in Melanocytic Lesions by Tissue Array. Possible Involvement in Tumor Progression. [Presented at the United States and Canadian Academy of Pathology Annual Meeting, September 2005].

Bedikian AY, Johnson MM, Broemeling LD, Papadopoulos NE, Kim KB, Camacho LH, Hwu P. Prognostic Factors Determining Long Term Survival of Patients with Unresectable Stage III and Stage IV Metastatic Melanoma (MM) Treated with Combination therapy or IL-2 based Biochemotherapy (BCC). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7544.

Vadhan-Raj S, Skibber JM, Crane C, Bueso-Ramos CE, Rodriquez-Bigas MA, Feig BW, Lin EH, Ajani JA, Collard M, Johnson MM, Hamilton SR, JanJan N. Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa (Procrit) in Patients with Rectal and Gastric Cancer Undergoing Chemo-Radiotherapy (CT/RT) Followed by Surgery: Early Termination of the Trial Due to Increase Incidence of Thromboembolic Events (TEE). [Poster presented at the American Society of Hematology 46th Annual Meeting, San Diego, CA, December 4-7, 2004].

Aloia T, Gershenwald JE, Ross MI, Lee JE, Johnson MM, Cormier JN, Ng C, Mansfield PF. Utility of CT and MRI Staging in Patients with Sentinel Lymph Node-Positive Melanoma. [Presented at the 4th International Sentinel Node Conference, Los Angeles, CA, December 3-6, 2004].

Gannon CJ, Rousseau Jr DL, Ross MI, Johnson MM, Lee JF, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy after previous wide local excision accurately reflects the status of the regional nodal basin in patients with primary melanoma. [Presented at the 4th International Sentinel Node Conference, Los Angeles, CA, December 3-6, 2004].

Pawlik TM, Ross MI, Johnson MM, Prieto VG, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma: Is there a role? [Poster presented at the 4th International Sentinel Node Conference, Los Angeles, CA, December 3-6, 2004].

Gershenwald JE, Prieto VG, Schacherer CW, Johnson MM, McClain DM, Mansfield PF, Lee JE, Ross MI. The impact of microscopic tumor burden in sentinel node-positive melanoma patients: Implications for future clinical trial design. [Presented at the Second International Melanoma Research Congress, Phoenix, AZ, November 13-16, 2004].

Pawlik TM, Ross MI, Johnson MM, Bedrosian I, Schacherer CW, Mansfield PF, Lee JE, Cormier JN, Gershenwald, JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. [Presented at the 57th Annual Meeting of the Society of Surgical Oncology, New York, NY, March 18-21, 2004].

Yang WT, Whitman GJ, Johnson MM, Bolanos-Clark M, Aldefer J, Kushwaha AC. Needle Localization for Excisional Biopsy of Breast Lesions: Comparison of Full Field Digital versus Screen-film Mammographic Guidance on Procedural Time. [Presented at the 88th Annual Meeting of the Radiological Society of North America, December 1-6, 2002].

Wang XS, Johnson MM, Broemeling LD, Janjan N, Komaki R, Mendoza T, Cleeland CS. Longitudinal Model for Cancer-Related Symptoms During Radiotherapy Among Patients with Gastrointestinal and Lung Cancer. [Poster presented at the Annual Meeting of the International Society for Quality of Life Research, October 30 - November 2, 2002].

Gayed I, Boccalandero F, Sdringola S, Johnson M, Butler C, Gee-Johnson S, Swafford I. Comparison of Resting Echocardiography and Gated SPECT in the Evaluation of Wall Motion Abnormalities. [Accepted for poster presentation at the 7th Annual Meeting of the American Society of Nuclear Cardiology, September 26-29, 2002].

Gayed IW, Vu TT, Macapinlac HA, Johnson MM, Delpassand ES, Wong F, Kim E, Podoloff DA. Comparison of Bone and F-18 FDG Scans in the Evaluation of Bony Metastases. [Poster presented at the 49th Annual Meeting of the Society of Nuclear Medicine, June 15-19, 2002].

Gayed I, Sureshbabu W, Iyer R, Macapinlac H, Johnson M, Podoloff DA. Positron Emission Tomography Versus Computerized Tomography for the Identification of Melanoma Metastases. [Poster presented at the 49th Annual Meeting of the Society of Nuclear Medicine, June 15-19, 2002].

 

Updated January 31, 2012


© 2014 The University of Texas MD Anderson Cancer Center